Hayfin has anchored a €155 million continuation vehicle for Spanish healthcare investment firm Alantra, targeting its portfolio company Health in Code. The fund will allocate 25% of its capital for follow-on investments, signaling continued confidence in the healthcare technology sector.

Health in Code specializes in genetic diagnostics and precision medicine solutions, serving hospitals and research institutions across Europe. The continuation vehicle allows existing investors to extend their holdings while providing fresh capital for growth initiatives. This structure has become increasingly popular in the healthcare sector as investors seek to maximize returns from proven assets.

The deal highlights growing investor appetite for healthcare technology companies with strong intellectual property and scalable business models. With the continuation vehicle fully funded, Health in Code is positioned to expand its genetic testing capabilities and potentially pursue strategic acquisitions in the European market.